NovaBridge Biosciences
corporate_fare Company Profile
NovaBridge Biosciences (NASDAQ:NBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NBP spans 6-K, 4, 20-F.
Recent high-impact activity:
- NovaBridge Posts Mature Givastomig Phase 1b Data: 79% ORR, 16.9-Month PFS at 8 mg/kg
- NovaBridge Picks 8 mg/kg Givastomig Dose After FDA Aligns on Phase 3
- Visara Licenses VIS-102 for Neurotrophic Keratitis in $111M Deal
- Visara Licenses Next-Gen NGF Therapy for Neurotrophic Keratitis, Expanding Ophthalmology Pipeline
- NovaBridge Reports H1 2026 Loss of $37.9M, Cash Runway Through 2028
Financial Snapshot
Short Interest & Short Volume
6.89 days to coverFINRA reported short interest of 3,579,179 shares in NBP as of the October 30, 2026 settlement, a 3.3% decrease from the prior period — about 6.9 days to cover at its recent average daily volume. On November 20, 2026, 33.5% of NBP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NBP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.